Synthesis and SAR of pyrimidine-based, non-nucleotide P2Y14 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 10, 2011, Pages 2832-2835

  Guay, Daniel ^a   Beaulieu, Christian ^a   Belley, Michel ^a   Crane, Sheldon N ^a   DeLuca, Jeancarlo ^a   Gareau, Yves ^a   Hamel, Martine ^a   Henault, Martin ^a   Hyjazie, Huda ^a   Kargman, Stacia ^a   Chan, Chi Chung ^a   Xu, Lijing ^a   Gordon, Robert ^a   Li, Lianhai ^a   Mamane, Yael ^a   Morin, Nicolas ^a   Mancini, Joseph ^a   Thérien, Michel ^a   Tranmer, Geoffrey ^a   Truong, Vouy Linh ^a   Wang, Zhaoyin ^a   Black, W Cameron ^a   more..

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Antagonist; Bioavailable; GPR105; Non nucleotide; P2Y14; Pyrimidine

Indexed keywords

PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y14 RECEPTOR ANTAGONIST; PURINERGIC RECEPTOR BLOCKING AGENT; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; REACTION OPTIMIZATION; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; MICE; MOLECULAR STRUCTURE; PAN TROGLODYTES; PURINERGIC P2 RECEPTOR ANTAGONISTS; PYRIMIDINES; RECEPTORS, PURINERGIC P2; STRUCTURE-ACTIVITY RELATIONSHIP;

MUS;

EID: 79955555317     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.03.084     Document Type: Article

References (16)

1. C. Williams, and S.J. Hill Methods Mol. Biol. 552 2009 39
2. M.D. Thompson, M.E. Percy, W. McIntyre Burnham, and D.E. Cole Methods Mol. Biol. 448 2008 109
3. P.M. Conn, A. Ulloa-Aguirre, J. Ito, and J.A. Janovick Pharmacol. Rev. 59 2007 225
4. D. Lecca, and S. Ceruti Biochem. Pharmacol. 75 2008 1869
5. G. Burnstock Cell. Mol. Life Sci. 64 2007 1471
6. K.A. Jacobson, A.A. Ivanov, S. de Castro, T.K. Harden, and H. Ko Purinergic Signalling 5 2009 75
7. R.L. Carter, I.P. Fricks, M.O. Barrett, L.E. Burianek, Y. Zhou, H. Ko, A. Das, K.A. Jacobson, E.R. Lazarowski, and T. Harden Mol. Pharmacol. 76 2009 1341
8. M. Scrivens, and J.M. Dickenson Eur. J. Pharmacol. 543 2006 166
9. L. Skelton, M. Cooper, M. Murphy, and A. Platt J. Immunol. 171 2003 1941
10. J.K. Chambers, L.E. Macdonald, H.M. Sarau, R.S. Ames, K. Freeman, J.J. Foley, Y. Zhu, M.M. McLaughlin, P. Murdock, L. McMillan, J. Trill, A. Swift, N. Aiyar, P. Taylor, L. Vawter, S. Naheed, P. Szekeres, G. Hervieu, C. Scott, J.M. Watson, A.J. Murphy, E. Duzic, C. Klein, D.J. Bergsma, S. Wilson, and G.P. Livi J. Biol. Chem. 175 2000 10767
11. T. Muller, H. Bayer, D. Myrtek, D. Ferrari, S. Sorichter, M.W. Ziegenhagen, G. Zissel, J.C. Virchow Jr., W. Luttmann, J. Norgauer, F. Di Virgilio, and M. Idzko Am. J. Respir. Cell. Mol. Biol. 33 2005 601
12. I.P. Fricks, S. Maddileti, R.L. Carter, E.R. Lazarowski, R.A. Nicholas, K.A. Jacobson, and T.K. Harden J. Pharmacol. Exp. Ther. 325 2008 588
13. A. Das, H. Ko, L.E. Burianek, M.O. Barrett, T.K. Harden, and K.A. Jacobson J. Med. Chem. 53 2010 471
14. J.P. Wolfe, R.A. Singer, B.H. Yang, and S.L. Buchwald J. Am. Chem. Soc. 121 1999 9550
15. M.J. Robins, and B. Uznanski Can. J. Chem. 59 1981 2608
16. D. Ok, C. Li, C. Abbadie, J.P. Felix, M.H. Fisher, M.L. Garcia, G.J. Kaczorowski, A. Kathryn, K.A. Lyons, W.J. Martin, B.T. Priest, M.M. Smith, B.S. Williams, M.J. Wyvratt, and W.H. Parsons Bioorg. Med. Chem. Lett. 16 2006 1358